News,  Webinars,  Publications



20 September 2017

Working closely with a large pharma partner, Sanoosa received promising test results for Sanoosa’s Nav1.7 ion-channel inhibitor program and for another undisclosed target. The results for Nav1.7 delivered a novel scaffold which is now the basis to computationally design compounds for Nav1.7 inhibitors with higher specificity and selectivity. 


13 September 2017 

Sanoosa and Circa Group sign MOU to collaborate on developing molecules showing early-stage promise in inhibiting protein-protein interactions.  


16 May 2017 

Changing Habits Pty Ltd has launched Sanoosa’s products for preventing inflammation  and for preventing hypercholesterolemia  into the Australian market. Concurrently, Changing Habits makes the products also available to its overseas customers.


16 May 2017 

A NATURAL APPROACH - MERGING SCIENCE & NATURE: Changing Habits / Sanoosa interview on disease prevention: .


23 November 2016 

Sanoosa Pty Ltd. enters a licensing agreement with Sunshine Coast /Australia based Changing Habits Pty Ltd to commercialize Sanoosa’s products for preventing inflammation  and for preventing hypercholesterolemia .




Coming soon:   


Small Molecule Protein-Protein Interaction Inhibitors


Stay tuned for a FREE webinar with an introduction to new developments in drug discovery where computational methods will play a bigger if not a dominant role in the early stages in drug development in the future.  


Small Molecule Protein-Protein-interaction inhibitors (smPPII) are an emerging drug class which recently has entered the discussion of drug discovery and R&D productivity. By targeting “hot spots” on the protein surface, small molecules have shown to be able to disrupt effectively protein-protein interactions. This approach seem to decrease risks for later drug development stages.  


Computational methods applied for the discovery and design of appropriate smPPII compounds have proven to deliver better quality in significant shorter time and substantial lower cost.  


In combination, computational discovery and design methods and smPPIIs provide a double de-risk strategy in drug development and create a quantum leap in R&D productivity.  


This webinar discusses our experience in this field and the implications on the early drug discovery phase in particular.

Selected Publications: 


  • Stehn JR, Haass NK, Bonello T, Desouza M, Kottyan G, Treutlein HR, et al. A novel class of anticancer compounds targets the actin cytoskeleton in tumor cells. Cancer Research. 2013 Aug 15;73(16):5169–82.
  • Stehn J, Haass NK, Bonello T, Desouza N, Kottyan G, Treutlein HR, Zeng J, Nascimento PRBB, Sequeira VB, Tanya L. Butler TL, Allanson M, Fath T, Hill  TA, McCluskey A, Schevzov G, Palmer SJ, Hardeman EC, Winlaw D, Reeve VE, Dixon I, Weninger W, Cripe TP, Gunning PW. A novel class of anti cancer compounds which target the actin cytoskeleton of tumor cells, Cancer Research, vol. 73, no. 16, pp. 5169–5182, Aug. 2013.
  • Burns CJ, Bourke DG, Andrau L, Xianyong Bu, Charman SA, Donohue AC, Fantino E, Farrugia M, Feutrill JT,  Joffe M, Kling MR, Kurek M, Nero TL, Nguyen T, Palmer JT, Phillips I, Shackleford DM, Sikanyika H, Styles M, Su S, Treutlein HR, Zeng J, Wilks AF, Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs). Bioorganic & Medicinal Chemistry Letters, 2009.
  • First paper on the successful design of a protein-protein interaction inhibitor: Zeng J, Thao Vuong-Nhen, Anna Zorzet, Bruno Catimel, Ed. Nice, Antony W. Burgess, Treutlein HR, Protein Engineering 14 (2001) 39, “Computational combinatorial design of short peptides that interfere with Ras-Raf association in vitro”.
  • This paper describes our early version of the MFMD method: Zeng J., Treutlein HR, A method for computational combinatorial peptide design of inhibitors of Ras. Protein Engineering 12, 457-468, 1999.
  • Groenen L.C., Walker F., Burgess A.W., Treutlein HR. A Model for the Activation of the Epidermal Growth Factor Receptor Kinase: Involvement of an Asymmetric Dimer? Biochemistry 36 (13), 3826-3836, 1997.
  • Treutlein HR, Schulten K, Brunger AT, Karplus M, Deisenhofer J, Michel H. Chromophore-protein interactions and the function of the photosynthetic reaction center: A molecular dynamics study, PNAS 89, 75-79, 1992.
  • Treutlein HR, Lemmon MA, Engelman DM, Brunger AT. The Glycophorin A transmembrane domain dimer: Sequence-specific propensity for a right-handed supercoil of helices.  Biochemistry 31, 12726-12733, 1992.


A complete list is available from Herbert's ORCID site:

This website makes use of cookies. Please see our privacy policy for details.

This website makes use of cookies. Please see our privacy policy for details.